Starting Thursday, a new Maryland law shields veterinarians from professional disciplinary action by the State Board of Veterinary Medical Examiners for discussing or recommending medical cannabis for animal patients. Governor Wes Moore signed the legislation earlier this year, creating a safe harbor for practitioners who previously risked losing their licenses due to federal scheduling conflicts and restrictive state medical boards. While federal law still classifies cannabis as a Schedule I substance, state-level protections continue to expand into uncharted veterinary territory.
This policy shift addresses a growing demand from pet owners seeking alternative treatments for chronic pain, anxiety, and seizures in domesticated animals. Veterinarians can now guide clients on dosing and cannabinoid formulations without fear of regulatory retribution—a major hurdle that historically left pet owners to navigate the nascent pet-cannabis market alone. The law does not automatically establish a regulated supply chain for animal-specific cannabis products, meaning veterinarians will likely recommend human-market medical products or specialized hemp-derived alternatives.
Dispensary operators and brand managers should monitor how this dynamic influences foot traffic and product inquiries, particularly regarding pet-safe tinctures, topicals, and low-THC formulations. As more states observe Maryland's approach, the integration of veterinary medicine into the broader cannabis ecosystem could accelerate, opening new distribution channels for brands capable of meeting stringent quality and dosing standards for animals.